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Summary Malignant carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid are
tumours with similar clinical features. In patients with unresectable or metastatic tumours leukocyte interferon
(IFN) and recombinant human (rh) IFN have demonstrated efficacy. Twenty-four evaluable patients with
progressive tumours were treated with 2.5 megaunits rh IFN a-2b, administered once daily subcutaneously, for
a median duration of 7 months (range 0.5-37+). Two carcinoid patients demonstrated a response in tumour
size, 80% showed stable disease (SD). Sixty percent of the carcinoid patients with elevated urinary 5-
hydroxyindoleacetic (5-HIAA) levels reached a biochemical partial response of the urinary 5-HIAA levels
(median duration 13.5 months). In the patients with an islet cell or medullary tumour and an elevated tumour
marker, the marker did not further increase. Of the 12 carcinoid patients evaluable for a symptomatic
response, ten (83%) experienced a relieve of symptoms. IFN a-2b dose reduction or discontinuation due to
toxicity was necessary in three and ten patients, respectively. No neutralising IFN a-2b antibodies developed
despite prolonged treatment.
In conclusion, IFN a-2b had a beneficial effect in patients with progressive tumours, while long-term IFN
a-2b treatment did not augment neutralising antibodies. In view of the IFN a-2b-related toxicity, administra-
tion of IFN a-2b on alternating days may be preferable.
Malignant carcinoid tumours, islet cell tumours and medul-
lary carcinomas of the thyroid are neuroendocrine tumours
considered to originate from the neural crest (Pearse, 1969).
Together with others such as pheochromocytomas, neurob-
lastomas and small cell lung carcinomas, they share the
ability to decarboxylate amines and are called APUD (amine
precursor uptake and decarboxylation) tumours. Carcinoid
tumours, islet cell tumours and medullary carcinomas of the
thyroid in many cases have similar clinical features, often
characterized by symptoms caused by their secretory prod-
ucts. The treatment should therefore address both tumour
growth and these symptoms. As these tumours are often
slowly progressive, surgery is the primary form of treatment.
In patients with unresectable or metastatic tumours, a variety
of cytotoxic drugs has been investigated (Kelsen et al., 1982;
Kvols, 1986a; Moertel et al., 1980). Because of the similar
properties, often common chemotherapy protocols are used
for the different manifestations of APUD tumours (Kelsen et
al., 1982; Kessinger et al., 1983). The most effective regimen
for carcinoid tumours appears to be the combination of
5-fluorouracil and streptozotocin (Moertel, 1987), with res-
ponse rates of 33%. Recently, the combination strep-
tozotocin and doxorubicin demonstrated considerable
efficacy for islet cell tumours with a response rate of 69%
(Moertel et al., 1992). Studies in patients with carcinoid
tumours or malignant endocrine pancreatic tumours treated
with human leukocyte interferon (Oberg et al., 1983; Eriks-
son et al., 1986; Oberg et al., 1986; Eriksson et al., 1987;
Oberg et al., 1989a) and recombinant human interferon alpha
(IFN-a) (Oberg et al., 1989b; Moertel et al., 1989; Smith et
al., 1987; Hanssen et al., 1989; Veenhof et al., 1992) have
demonstrated response rates of 47-77% and 36-55%, respec-
tively. Responses in all studies mainly consisted of a reduc-
tion in tumour marker levels and an amelioration of clinical
symptoms.
We conducted a trial with recombinant human IFN a-2b
administered daily to patients with progressive malignant
carcinoid tumours, islet cell tumours and medullary car-
cinomas of the thyroid. In addition, apart from the urinary
5-hydoxyindoleacetic acid (5-HIAA) level, the significance of
platelet serotonin levels, serum or plasma levels of neuron-
specific enolase (NSE), and urinary levels of serotonin,
catecholamine and histamine as markers for the diagnosis
and course of carcinoid tumours was studied during IFN
a-2b treatment.
Finally, the development of neutralising IFN a-2b
antibodies during long-term IFN treatment was studied, since
neutralising antibodies can develop during IFN a-2b treat-
ment (Spiegel et al., 1986; Oberg et al., 1989b).
Patients and methods
Patients, less than 80 years of age, with histologically proven
malignant carcinoid tumour, islet cell carcinoma or medul-
lary carcinoma of the thyroid, were entered in the study. Only
patients with evidence of progressive disease (either tumour
lesion, tumour markers or symptoms), not amenable to
surgery, and evaluable for response by measurable tumour
lesions and/or tumour markers were eligible. Patients with
severe heart, liver (serum total bilirubin > 25ytmol [') or
kidney impairment (creatinine clearance < 60 ml min-1)
were excluded from the study, as were patients with a WHO
performance score of 4 or with clinical signs of brain involve-
ment. Chemotherapy and surgery within three weeks prior to
entry were exclusion criteria, as was prior radiotherapy to the
indicator lesion. At entry leukocyte counts > 3.0 x I0'1-
and platelet counts > 100 x 1091-' were required.
Recombinant human IFN a-2b (Intron A, Schering-Plough
Corporation, Kenilworth, USA) was administered once daily
by subcutaneous (sc) injection. The initial dose was 2.5
megaunits (MU) per day. Oncology nurses provided instruc-
tions for the self administration of IFN a-2b. The IFN-
related side effects such as fever, flu-like symptoms and
anorexia were graded for severity (Table I). Paracetamol up
to 3 g/day was used against fever and flu-like symptoms
encountered during the first days of treatment. For IFN-
related toxicity grade II the IFN a-2b dosage was reduced to
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Table I Grading of IFN a-2b-related toxicity
Grade I II III
Fever > 38°C > 39°C > 40C
Flu-like symptoms <3 days 3-7 days > 7 days
Fatigue <7 days 7-14 days > 14 days
Anorexia <7 days 7-14 days > 14 days
Weight loss <2 kg 2-5 kg >5kg
50%. If grade II toxicity persisted, treatment was discon-
tinued until sufficient (grade I or less) recovery of the patient.
If recovery occurred within 14 days, the dosage was resumed
at 50%, otherwise the patient was taken off study. The
patient was also taken off study if grade II toxicity recurred
at the 50% dosage. In the event of serious IFN-related
toxicity (grade III), treatment was also discontinued. The
IFN dosage was reduced to 50% for leukocyte counts
< 2.0 x 109 1' or platelet counts < 50 x 109 1').
IFN a-2b treatment was continued until progressive
disease occurred. Patients were considered evaluable for res-
ponse, if IFN a-2b had been administered for at least three
months. Evaluation of tumour size was performed at entry
and every 3 months during IFN a-2b treatment. Evaluation
of relevant tumour markers occurred at entry and every 4
weeks during treatment. Patients showing progressive disease
during the first 3 months of treatment were taken off study
and recorded as progressive disease. The study was approved
by the Medical Ethical Committee of the University Hospital
of Groningen. All patients gave their informed consent.
The duration of complete response (CR), defined as disap-
pearance of all measurable and evaluable tumour lesions and
return of elevated marker levels to normal values for at least
4 weeks, was calculated from the moment CR was first
recorded until progression. The duration of partial response
(PR), defined as over 50% reduction in the product of the
greatest tumour diameter and its perpendicular for all
measurable tumour lesions or a 50% reduction in the level of
markers during two consecutive measurements not less than
4 weeks apart, was calculated from commencement of treat-
ment until progression. Stable disease (SD) was defined as a
reduction in measurable disease of less than 50%, or an
increase in tumour size of less than 25% for at least 12
weeks. The biochemical response was defined as SD in case
of less than 25% increase or less than 50% decrease of the
marker levels during at least 4 weeks. The duration of SD
was calculated from the start of treatment until progression.
Progressive disease (PD) was the appearance of any new
tumour lesions, the increase by more than 25% of
measurable lesions or an increase in marker levels by more
than 25% for a minimum of4 weeks. At entry and at regular
intervals during IFN treatment a complete physical examina-
tion, blood counts, and blood chemistry were performed.
Tumour markers
The concentration of 5-HIAA in 24 h urine (normal value
0.8-3.8 mmol mol'- creatinine), collected in 2 liter brown
polypropylene bottles (Sarsted, Nuembrecht, Germany) con-
taining 250 mg each of Na2S205 and EDTA as preservatives,
was determined in ether extracts, using high performance
liquid chromatography with fluorometric detection (Rosano
et al., 1982). Urinary catecholamines and metabolites levels
were measured as described previously (Muskiet et al., 1979;
Muskiet et al., 1981), as were urinary histamine and
metabolites levels in 24-h urine (Keyzer et al., 1983).
Serotonin contents of urine (normal value 25-66tsmol mol'
creatinine) and of platelet rich plasma (normal value
<0.5-33.3 nmol 1-' plasma) were determined using high
performance liquid chromatography with fluorometric detec-
tion (Kema et al., 1992, in press). Platelet serotonin contents
(normal value 2.8-5.4nmol I0-9 platelets) were determined
as described previously (Kwarts et al., 1984). Venous blood
samples were drawn in 10 ml vacutainer tubes (Becton-
Dickinson, Meylan Cedex, France) containing 0.12 ml
(0.34 mol I') EDTA solution, and were immediately put on
ice. Platelet serotonin contents were calculated by dividing
the concentration of serotonin in platelet rich plasma by its
platelet concentration. Platelet concentrations were measured
with a Coulter counter model S plus 4 (Coulter Electronics,
Hialeah, USA).
Calcitonin serum levels (normal value < 300ngl1') were
measured with a radioimmunoassay (Incstar Corporation,
Stillwater, USA), as were gastrin serum levels (normal value
< 100 ng -l1), Becton Dickinson and Company, New York,
USA). NSE levels in haemoglobin free serum or plasma
samples (normal value < 12.5 jig 1-l) were measured in dup-
licate with a radioimmunoassay (Pharmacia Diagnostics AB,
Uppsala, Sweden), Tumor Necrosis Factor alpha (TNF-a)
plasma levels (detection limit 5 ng l-') with a radioim-
munoassay (Medgenix, Brussels, Belgium).
Anti IFN x-2b antibody serum levels were measured at
entry and at any time point during IFN treatment at which
there was a change in the clinal condition, tumour markers
or tumour response. An enzyme-linked immunosorbent assay
was used with as antibody the Intron A-specific mouse
monoclonal antibody MC-16 (developed by TNO, Rijswijk,
the Netherlands). As a negative control, pooled normal
human serum obtained from healthy donors was included in
the test. None of the donors had ever received IFN. This
control serum contained naturally occurring anti-human
IFN-a autoantibodies, the occurence of which has been
reported previously (Ross et al., 1990). This natural titer was
abstracted as a blank value.
Results
Patient characteristics
Patient characteristics are shown in Table II. Twenty patients
with a malignant carcinoid tumour, two with an islet cell
carcinoma and two with a medullary carcinoma of the
thyroid gland were entered. Out of the 20 patients with a
malignant carcinoid tumour 13 patients had clinical symp-
toms of a carcinoid syndrome (flushing, diarrhea, asthma), 17
patients had hepatic metastases. Two patients had lymph
node metastases and one patient had a metastasis in the
parotid gland. Both patients with an islet cell carinoma and
one patient with a medullary carcinoma of the thyroid had
Table II Patient characteristics
Metastases
Liver Lymph nodes Parotid gland
Median age in years (range) 58.5 (36-79)
Male/female 14/10
Tumour type (number of patients)
Carcinoid 20 17 2 1
mid-gut 11
rectal 3
pulmonary 4
unknown 2
Medullary thyroid carcinoma 2 1 1
Islet cell carcinoma 2 2 -852 B. BIESMA et al.
hepatic metastases, while the other patient with a medullary
carcinoma had lymph node metastases.
IFNa-2b effect on tumour lesions
All patients had evaluable tumour lesions at entry. Twenty-
two of the 24 patients were evaluable for response (Table
III). After 2 weeks one patient was taken off study because
cerebral metastases became manifest and in one patient treat-
ment was discontinued within three months due to IFN
a-2b-related fatigue and anorexia. One patient (mid-gut car-
cinoid) reached a CR of multiple liver metastases and one
patient (mid-gut carcinoid) a PR of the solitary liver metas-
tasis which permitted a hemihepatectomy. This last patient is
without evidence of disease 31 + months after hemihepatec-
tomy. Sixteen patients showed SD (median duration 6.5
months, range 3-37 + months). Two patients had PD at the
first evaluation after three months of IFN a-2b treatment,
while in two other patients (one patient with a carcinoid
tumour and one patient with an islet cell tumour) treatment
was discontinued within the first three months because of
rapidly progressive disease.
IFNa-2b effect on tumour markers
In six out of ten evaluable patients with a malignant car-
cinoid tumour and elevated pretreatment urine 5-HIAA
levels a biochemical PR (median duration 13.5 months, range
1-37 + months) was achieved (Table IV). In all patients
responses occurred within the first three months of treatment.
Four patients showed SD (median duration 6.5 months,
range 3.5-17 months). In 60% of the carcinoid patients
urine serotonin levels were elevated at entry. One patient had
an increased urine serotonin level while having a normal
urine 5-HIAA level. Of five patients evaluable for response,
two had a biochemical PR (6 and 9 months, respectively) and
three had SD (median duration 8 months, range 4.5 + -18
months). Eight carcinoid patients with increased pretreatment
platelet serotonin contents were evaluable for response. Two
patients, both with normal urine 5-HIAA levels, reached a
biochemical PR (duration 5 and 6 months, respectively),
Table III Response tumour size to IFN treatment
CR PR SD PD
Number of evaluable patients 22 1 la 16b 4
Carcinoid tumour 18 1 1 13 3
Islet carcinoma 2 - - 1 1
Medullary thyroid carcinoma 2 - 2 -
CR: complete remission, PR: partial remission, s.d.: stable disease,
PD: progressive disease. aDuration 14 months. bMedian duration 6.5
months (range 3-37 + ).
while six patients, all with elevated urine 5-HIAA levels, had
SD (median duration 12 months, range 6.5-27 months).
Both patients with a medullary carcinoma of the thyroid
gland and increased calcitonin serum levels at entry had also
SD (duration 3.5 and 4 months respectively). The only
patient with increased gastrin serum levels had SD with a
duration of 5 months.
In 16 patients NSE serum or plasma levels were measured
before the start of treatment. In five patients NSE levels were
increased. Three of these patients showed no other elevated
tumour markers (two patients with a rectal carcinoid and one
patient with an islet cell carcinoma). The patient with the
islet cell carinoma was not evaluable for marker response. All
four evaluable patients had SD during IFN a-2b treatment
(median duration 5.5 months).
In none of the patients with a malignant carcinoid tumour
urinary catecholamine and metabolites, or histamine and
metabolites excretion were increased at entry. Therefore these
markers could not be used for evaluation of an IFN a-2b
effect.
IFN o-2b effect on clinical symptoms
Thirteen patients with a malignant carcinoid tumour showed
symptoms of the carcinoid syndrome (flushing, diarrhea or
asthma). Ten out of 12 evaluable patients experienced a
disappearance or reduction in flushing (eight patients) and/or
diarrhoea (seven patients), while one of these patients also
had less asthmatic symptoms. A symptomatic improvement
occurred within the first month of treatment in all patients.
Five of these patients demonstrated a PR and two a s.d. of
the urinary 5-HIAA excretion. The other three patients with
improving clinical symptoms were not evaluable for this
biochemical marker. In two patients the frequency offlushing
remained stable during IFN a-2b treatment. One of these two
patients reached a PR, while the other showed no change in
the urinary 5-HIAA excretion.
IFNa-2b toxicity
The median duration of IFN a-2b treatment was 7 months
(range 0.5-37 + months). One patient (carcinoid) was con-
sidered not evaluable for toxicity due to cerebral metastases
within two weeks after start of treatment. The most fre-
quently occurring side effects were 'flu-like symptoms', con-
trollable with Paracetamol, in 57% of the patients during the
first days of IFN treatment. Anorexia and nausea were noted
in 35% and 26% of the patients, respectively, fatigue was
reported by 30%. Pruritus occurred in 17%, while two
patients experienced a blurred vision during treatment. In
three out of 23 patients IFN treatment was discontinued
because of anorexia combined with fatigue in two patients
(after 2 weeks and 20.5 months treatment, respectively) and a
Table IV Response of elevated tumour markers during a-IFN treatment
Number of evaluable Number (%) Median duration of
patients of responders response in months (range)
Urinary 5-HIAA 10
PR 6 (60) 13.5 (1-37+)
SD 4 (40) 6.5 (3.5-17)
Urinary serotonin 5
PR 2 (40) 7.5 (6-9)
SD 3 (60) 8 (4.5-18)
Platelet serotonin 8
PR 2 (25) 5.5 (5-6)
SD 6 (75) 12 (6.5-27)
Calcitonin 2
PR 0 (0)
SD 2 (100) 3.8 (3.5-4)
Gastrin 1
PR 0 (0)
SD 1 (100) 5
NSE 4
PR 0 (0)
SD 4 (100) 5.5 (4-14.5)IFN a-2B EFFECT ON PROGRESSIVE TUMOURS 853
large persisting infiltrate at the IFN injection site in one
patient (after 17.5 months). IFN-related toxicity necessitated
dose-reduction in ten out of 23 patients. In five the IFN dose
was reduced because of fatigue (two patients), anorexia,
nausea or conjunctivitis, respectively. In the five other pa-
tients a combination of these symptoms made IFN dose
reduction necessary. In addition, in two of the above men-
tioned patients leukocytopenia WHO grade III occurred. In
one of these two also thrombocytopenia grade III was
noticed. Leukocytopenia grade I and II occurred in 39% and
30%, respectively, thrombocytopenia grade I and II occurred
in 13% and 4% of the patients.
In none of the patients an increase in anti IFN x-2b
antibody serum levels during IFN treatment was detected. In
16 patients TNF-a plasma levels were measured at entry.
While levels were increased in four patients at entry (median
136.5ngl-', range 74-291), in none of the patients an in-
crease in TNF-a plasma levels during IFN treatment could
be demonstrated.
Discussion
In this study we evaluated the efficacy and tolerability of IFN
a-2b in patients with progressive malignant APUD tumours.
A 50% reduction in urinary 5-HIAA levels was reached in
60% of the carcinoid patients with elevated 5-HIAA levels. A
reduction in tumour size was recorded in only two patients,
while 73% demonstrated a SD. However, it has been recently
demonstrated that in carcinoid metastases of the liver a
reduction of the amount of tumour tissue, in spite of
unaltered metastatic size, can be achieved by IFN a treat-
ment (Andersson et al., 1990). These results seem comparable
with results from other studies. Several studies describe the
efficacy of IFN a treatment in patients with malignant car-
cinoid tumours. Oberg et al. treated 20 patients for six
months with IFN ox-2b, administered sc at a mean dose of
5.9 MU three times weekly (Oberg et al., 1989b). In 50% of
their patients at least a 50% reduction in urinary 5-HIAA
levels was reached, lasting a minimum of 5 months, while
30% had SD and 15% had PD. No significant reductions in
tumour size were obtained. Smith et al. treated 14 patients
for a median time of fourteen weeks (range 4-52 weeks) with
IFN a-2b sc three times weekly at doses of 2-10 MUm2
(Smith et al., 1987). Although no tumour regressions were
seen, 36% of the patients reached a 50% decrease in urinary
5-HIAA levels for a median time of 16 weeks (range 8-20
weeks). Other investigators observed in 40% of the patients a
50% reduction of the urinary 5-HIAA levels after one year
of IFN a-2b treatment at a median dose of 5 MU/day sc
(Hanssen et al., 1989). In addition, a 50% reduction of the
area of the largest hepatic metastasis was reached in one
patient. A 50% reduction of urinary 5-HIAA levels was
reached in 33% of patients with a metastatic carcinoid
tumour treated with IFN a-2b at a dose of 3 MU thrice
weekly sc (Veenhof et al., 1992). Responses occurred within 8
weeks and rates did not improve by escalating the IFN a-2b
dose to maximally 12 MU thrice weekly. In only one patient
a PR of the tumour was obtained. Moertel et al. treated 27
patients for a median time of 8 weeks (Moertel et al., 1989)
with IFN a-2a intramuscularly three times weekly at doses of
6-24 mu m-2. Thirty-nine percent experienced a 50% re-
duction in elevated urinary 5-HIAA levels, with a median
duration of 28 days. In 20% of the patients a PR of the
indicator lesion was observed, with a median duration of 7
weeks (range 4-26). The results of our study and others with
IFN a are similar to those in which human leukocyte IFN
was administered to patients with a malignant carcinoid
tumour (Oberg et al., 1986) and are far superior to results of
current chemotherapeutic regimens (Kvols, 1986a; Moertel,
1987).
There are few reports on treatment of medullary thyroid carcinomas and malignant endocrine pancreatic tumours with
recombinant human IFN a. Anderson et al. unsuccessfully treated two patients with metastatic vipomas (Anderson &
Blood, 1987). Grohn et al. treated two patients with medul-
lary thyroid cancer with low dose IFN a-2b (Grohn et al.,
1990). This resulted in both patients in a decrease in cal-
citonin values (>50% and 25%, respectively) and improve-
ment of diarrhoea. In the present study two patients with a
medullary thyroid carcinoma and one patient with an islet
cell carcinoma reached a s.d. of both the tumour and the
biochemical marker.
Although urine 5-HIAA excretion is considered to be the
most reliable biochemical parameter for a serotonin secreting
tumour (Moertel, 1987), determination of urinary and plate-
let serotonin levels may provide additional information
(Feldman, 1986; Kema et al., 1992, in press). In our study
three carcinoid patients demonstrated elevated platelet sero-
tonin levels (two patients) or increased urinary serotonin
levels (one patient) in the absence of increased urine 5-HIAA
excretion. In 50% of the patients with a malignant carcinoid
tumour pretreatment levels of platelet serotonin were ele-
vated. Other studies demonstrated similar percentages (Feld-
man, 1986; Kema et al., 1992, in press). A comparison with
the urine 5-HIAA level as a marker for monitoring tumour
response is difficult due to the small number of patients.
However, increased platelet serotonin contents in two pa-
tients with normal urine 5-HIAA levels indicate that platelet
serotonin may be a more sensitive marker for carcinoid
tumours producing small amounts of serotonin, which results
in normal urine 5-HIAA excretion.
A role of NSE as a serum marker for the diagnosis of
neuroendocrine neoplasms and for monitoring the response
to therapy has been previously suggested (Prinz & Marangos,
1982; Prinz & Marangos, 1983; Prinz et al., 1983). NSE
serum levels were reported to be increased in 40-50% of
patients with APUD tumours. Our results confirm the role of
serum NSE as a useful marker for APUD tumours as three
patients did not have any other elevated tumour markers. In
our study 31% of the patients had increased NSE levels.
However, the group of patients (25%) evaluable for NSE
response to IFN a-2b, was too small to allow conclusions
with regard to a role in monitoring tumour response. Al-
though early studies reported increased urine catecholamine
and histamine levels in patients with carcinoid tumours
(Feldman et al., 1974; Roberts II et al., 1979; Pernow &
Waldenstrom, 1957), we did not find elevated levels of these
markers prior to IFN treatment. This may imply that these
markers may be of limited value for the diagnosis of car-
cinoid tumours.
In our study 83% of the patients with symptoms of the
carcinoid syndrome experienced a reduction in episodes of
diarrhoea and/or flushing. Other studies using IFN-x (Smith
et al., 1987; Hanssen et al., 1989; Moertel et al., 1989;
Veenhof et al., 1992) report similar results. It is unlikely that
increasing the IFN a-2b dose would have resulted in a higher
symptomatic response rate (Moertel et al., 1989; Veenhof et
al., 1992).
Side effects of IFN a-2b were similar as described pre-
viously for studies in APUD tumours at comparable doses
(Oberg et al., 1989b; Smith et al., 1987). Some side effects
(fatigue and anorexia) were observed more frequently by
Moertel et al. which may be attributed to the considerably
higher IFN adose used in that study (Moertel et al., 1989).
In our study, IFN dose-reduction or discontinuation was
necessary in 56% of the patients. This percentage is high
compared to other studies using comparable or moderately
higher doses of IFN (Smith et al., 1987; Hanssen et al.,
1989). However, these data are difficult to compare, as differ-
ent schedules for IFN dose-reduction may have been used.
One of the reasons of the relatively high frequency of IFN
dose-reduction may have been the daily administration of
IFN. In two studies using IFN three times per week the
authors were able to administer higher cumulative IFN doses
weekly (Smith et al., 1987; Oberg et al., 1989b). Administra-
tion of IFN a-2b did not result in an increase in TNF-a
plasma levels. In none of the patients in our study anti IFN
a-2b antibodies developed. Oberg et al., detected INF a-2b
antibodies in 15% of the carcinoid patients during the 6854 B. BIESMA et al.
months treatment period (Oberg et al., 1989b). In cancer
patients treated with systemic IFN a-2b, antibodies develop-
ed in 2.4% of the patients (Spiegel et al., 1986). Thus, our
data support the observation that anti IFN x-2b antibodies
develop in only a small percentage of the patients treated
with IFN a-2b. Therefore, treatment failure can only be
attributed to anti IFN a-2b antibodies in a minority of the
patients.
In conclusion, this study demonstrates that IFN a-2b can
be of therapeutical use in patients with progressive malignant
APUD tumours, as it may reduce both clinical symptoms
and levels of biochemical tumour markers. As is the case for
other treatment modalities the tumour-reducing effect is
limited, with objective tumour responses occurring in only a
small percentage of the patients. Although, in our opinion,
the improvement in quality-of-life status of the patients
outweighed the IFN a-2b-related side effects, a similar symp-
tomatic improvement can be reached with somatostatin ana-
logues almost without side effects (Kvols et al., 1986b; Vinik
et al., 1989). However, not all patients resistant to IFN a
treatment will benefit from somatostatin treatment and vice
versa. To limit side effects, IFN a-2b administration on
alternating days may be preferable. A role of NSE levels and
platelet serotonin contents as additional markers for car-
cinoid tumours was confirmed. However, the group of
patients evaluable for these markers was too small, to
confirm a possible role of these markers in monitoring
tumour response. Finally, it was demonstrated that even over
a prolonged period of time the development of neutralising
IFN x-2b antibodies did not occur, implying that IFN a-2b
treatment can be maintained over a long period of time in
patients with malignant APUD tumours without loss of
efficacy. This is of clinical importance as our study also
demonstrated that a number of patients benefitted from sus-
tained IFN a-2b treatment over a number of years.
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